Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H27FO5 |
| Molecular Weight | 378.4345 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@H](O)[C@H]3[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
InChI
InChIKey=MYYIMZRZXIQBGI-HVIRSNARSA-N
InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/13892052Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/5818823 | http://www.tabletwise.com/us/alphadrol-tablet
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13892052
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/5818823 | http://www.tabletwise.com/us/alphadrol-tablet
Fluprednisolone is glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated (hypersensitivity dermatoses, contact dermatitis, pemphigus, pemphigoid, lupus erythematosus, neoplasia etc), except adrenal deficiency states.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/92477 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ALPHADROL Approved UseUnknown Launch Date1978 |
|||
| Primary | ALPHADROL Approved UseUnknown Launch Date1978 |
|||
| Primary | ALPHADROL Approved UseUnknown Launch Date1978 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5.25 mg/m2 1 times / day multiple, oral Highest studied dose Dose: 5.25 mg/m2, 1 times / day Route: oral Route: multiple Dose: 5.25 mg/m2, 1 times / day Sources: |
unhealthy, 0-16 |
|
5.25 mg 1 times / day multiple, oral Dose: 5.25 mg, 1 times / day Route: oral Route: multiple Dose: 5.25 mg, 1 times / day Sources: |
unhealthy, children Health Status: unhealthy Age Group: children Sex: M+F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Intraocular pressure elevation from topical difluprednate use. | 2010-12 |
|
| Pathology in practice. Pemphigus foliaceous. | 2010-11-01 |
|
| Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. | 2010-10 |
|
| Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion. | 2010-08 |
|
| Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. | 2010-06 |
|
| New drugs 09, part 2. | 2009-06 |
|
| Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. | 2009-01 |
|
| New drugs: Clevidipine butyrate, difluprednate, and tetrabenazine. | 2008-11-21 |
|
| Effect of isoflupredone acetate with or without insulin on energy metabolism, reproduction, milk production, and health in dairy cows in early lactation. | 2007-09 |
|
| Effects of dexamethasone and isoflupredone acetate on plasma potassium concentrations and other biochemical measurements in dairy cows in early lactation. | 2006-07 |
|
| Topical steroid and antibiotic combination therapy in red eye conditions. | 2006-04 |
|
| Injection site with generalized rash caused by pegylated interferon alpha 2a injection. | 2006 |
|
| Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. | 2005-09-14 |
|
| Conjunctival lymphoid hyperplasia presenting with bilateral panuveitis. | 2005-03 |
|
| Cutaneous reactions to imatinib mesylate treated by topical steroid. | 2005-03 |
|
| [Traumatic lesion of the optic nerve head by flying fish: a case report]. | 2004-05 |
|
| Evaluation of exogenous glucocorticoid injection on preweaning growth performance of neonatal pigs under commercial conditions. | 2004-04 |
|
| Effects of two anti-inflammatory drugs on physiologic variables and milk production in cows with endotoxin-induced mastitis. | 2004-01 |
|
| Comparison of efficacy and tolerability of isoflupredone and dexamethasone in the treatment of horses affected with recurrent airway obstruction ('heaves'). | 2003-06 |
|
| Pharmacodynamics of isoflupredone acetate in an endotoxin-induced mastitis model. | 2003-03 |
|
| Analysis of an anti-inflammatory steroidal drug, difluprednate, in aqueous humor by combination of semi-micro HPLC and column switching method. | 2003-01-15 |
|
| Effect of chirality at C-20 of methyl 11beta,17alpha,20-trihydroxy-3-oxo-1,4-pregnadien-21-oate derivatives on antiinflammatory activity. | 2002-04 |
|
| [Severe hypokalemic episode induced by abuse of fluoro-prednisolone acetate administered nasally and the simultaneous oral consumption of indapamide]. | 1985-01-31 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13892052
A dose of 3 mg per kilogram in dogs for a period of two weeks produced no toxic effects.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5818823
Lymphosarcoma P1798 cells was treated with 9FP (Fluprednisolone). Ribonuclease activity of the cells was measured after incubation with 0.1 mkg/ml 9FP (Fluprednisolone) for various time periods (from 6 to 48 h). Cells also develop increased acid ribonuclease activity after incubation with 9FP (Fluprednisolone) in vitro.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D005477
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
3335
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
FLUPREDNISOLONE
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
DTXSID5046067
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
SUB07736MIG
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
53-34-9
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
C65730
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
m5493
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
1216
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
5876
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
1352
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
9H05937G3X
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
100000080742
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
47439
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
DB09378
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
200-170-8
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200774
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
4497
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | RxNorm |
ACTIVE MOIETY